Article Text

Download PDFPDF

868 Antibody blockade of the mono-ADP-ribosyltransferase ART1 promotes radiation-induced tumour infiltration of dendritic cells and potentiates tumour control by radiotherapy and CTLA-4 inhibition
  1. Ricardo M Sainz1,
  2. Sumit Mukherjee2,
  3. Jorge Humberto Rodriguez Quintero3,
  4. Qingyang Zhang1,
  5. Brendon M Stiles3 and
  6. Erik Wennerberg1
  1. 1The Institute of Cancer Research, London, UK
  2. 2Albert Einstein College of Medicine, Bronx, NY, USA
  3. 3Montefiore-Einstein Health System, Bronx, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Hypofractionated radiotherapy (RT) combined with anti-CTLA-4 antibodies has been shown to induce systemic anti-tumour immunity in anti-CTLA-4-refractory metastatic non-small cell lung cancer (NSCLC) patients.1 The immunogenicity of RT relies on its activation of conventional type I dendritic cells (cDC1s) which are essential for cross-priming of tumour-specific CD8 T cells, a process which is regulated by CTLA-4. We recently showed that tumour expression of mono-ADP-ribosyltransferase-1 (ART1) mediates immune resistance by using NAD+ to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) leading to NAD-induced cell death.2 Here, we assess whether P2X7R-expressing cDC1s are targeted by ART1, whether ART1-blockade modulates RT-mediated cDC1 tumour infiltration, and whether ART1-blockade potentiates synergy between RT and CTLA-4-blockade in the immunotherapy-resistant Lewis Lung Carcinoma (LLC1) model.

Methods An etheno-NAD (e-NAD) assay was used to assess MARylation of bone marrow-derived cDC1s co-cultured with recombinant ART1 (rART1) and ART1-blockade using a novel monoclonal ART1 blocking antibody, 22C12.2 C57BL/6J mice were inoculated with LLC1 flank tumours on day 0 and randomized into treatment groups: (1) iso ctrl, (2) aCTLA-4, (3) aART1, (4) aCTLA-4+aART1, (5) RT+iso ctrl, (6) RT+aCTLA-4, (7) RT+aART1, and (8) RT+aCTLA-4+aART1. Image-guided RT was delivered to the tumours on day 7–9 as 8 Gy fractions on consecutive days. ART1-blockade using 22C12 and CTLA-4-blockade using 9H10 started on day 7 and 9 respectively. Antibodies were delivered intraperitoneally every three days until end of study. Tumours were harvested for flow cytometry analysis on day 14 (non-irradiated mice) and on day 23 (irradiated mice).

Results cDC1s were MARylated in the presence of rART1 primarily affecting the P2X7R+ cDC1 population that lacked co-expression of the NAD-cyclase CD38. In this population, 76.1±4.8% of cells were MARylated following co-culture with rART1 compared with 16.9±18.3% of cells cultured with e-NAD alone. Addition of ART1-blockade reduced MARylation of P2X7R+CD38- cDC1s to 26.1±19.3% (figure 1A). ART1-blockade resulted in a significant tumour enrichment of cDC1s in irradiated mice (p<0.01) but not in non-irradiated mice (figure 1B). In irradiated mice, combined ART1-blockade and CTLA-4-blockade delayed tumour progression of LLC-1 tumours compared to RT alone (p<0.01), which was not observed with aCTLA-4 or aART1 alone (figure 1C).

Conclusions Our findings indicate that ART1 MARylates cDC1s in vitro and abrogates radiation-induced tumour infiltration of cDC1s in vivo. Further, ART1 blockade potentiates the anti-tumour effect of RT and CTLA-4-blockade in an immunotherapy-resistant lung cancer model, warranting further exploration of ART1-blockade in NSCLC to increase patient responsiveness to CTLA-4-blockade and radiotherapy.

Acknowledgements This work is supported by an ASPIRE Award from the Mark Foundation.


  1. Formenti SC, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med, 2018;24(12):1845–1851.

  2. Wennerberg E, et al. Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. Sci Transl Med, 2022;14(636):eabe8195.

Abstract 868 Figure 1

(A) Etheno-NAD (e-NAD) assay determining MARylation of bone-marrow derived cDC1s. cDC1s were incubated for 2 hours with e-NAD alone or with e-NAD and recombinant ART1 (rART1) in the presence or absence of 22C12 ART1 -blocking antibody (aART1). After coculture, cDC1s were analysed by flow cytometry for ART1-mediated MARylation by e-NAD staining and co-stained for P2X7R and the NAD-cyclase CD38. One-way ANOVA with Tukey’s test for multiple comparisons.(B) Percentage of cDC1 cells among total tumour-infiltrating DCs in LLC1 tumours. Non-irradiated tumours (no RT) were harvested on day 15 and irradiated tumours (RT) were harvested on day 24 after tumour inoculation. Two-tailed t-test with Welch’s correction. (C) Growth curve of subcutaneous flank LLC1 tumours (n=5 mice/group). Two-way repeated-measures ANOVA. *p<0.05, **p<0.01, ****p<0.0001

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.